Library — CHDR

Search

Filter

White Blood Cell and Platelet Counts Are Not Suitable as Biomarkers in the Differential Diagnostics of Dementia.

Schröder S, Heck J, Groh A, Frieling H, Bleich S, Kahl KG, Bosch JJ, Krichevsky B, Schulze-Westhoff M

Brain sciences, 2022 Oct

View publication
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.

Dijkstra F, O'Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, Zuiker R, van Gerven J, Jacobs G

Translational psychiatry, 2022 Sep; 12(1):408

View publication
Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder

A.Safai Pour, S.J.M.van der Aalst, I.J.Brouwer, E.J.Giltay, G.E.Jacobs, N.J.A.van der Wee, A.M.van Hemert, M.S.van Noorden

Journal of Affective Disorders Reports, 2022 Aug

View publication
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Dijkstra FM, Zuiker RGJA, Siebenga PS, Leigh-Pemberton RA, Sun L, Manthis JD, de Kam ML, Lin R, von Moltke LL, Rezendes D, van Gerven JMA

British journal of clinical pharmacology, 2022 Jun; 88(6):2909-2925

View publication
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.

Dijkstra FM, van de Loo AJ, Abdulahad S, Bosma ER, Hartog M, Huls H, Kuijper DC, de Vries E, Solanki B, Singh J, Aluisio L, Zannikos P, Stuurman FE, Jacobs GE, Verster JC

Journal of psychopharmacology (Oxford, England), 2022 May; 36(5):614-625

View publication
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder

Francis M Dijkstra, Aurora JAE van de Loo, Smedra Abdulahad, Else R Bosma, Mitch Hartog, Hendrikje Huls, Dianne C Kuijper, Esther de Vries, Bhavna Solanki, Jaskaran Singh, Leah Aluisio, Peter Zannikos, Frederik E Stuurman, Gabriël E Jacobs, Joris C Verster

Journal of Psychopharmacology, 2022 Feb

View publication
MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants

T. Cholewinski, D. Pereira, M. Moerland, G. Jacobs

Therapeutic Advances in Psychopharmacology, 2021 Oct

View publication
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.

Sverdlov O, Curcic J, Hannesdottir K, Gou L, De Luca V, Ambrosetti F, Zhang B, Praestgaard J, Vallejo V, Dolman A, Gomez-Mancilla B, Biliouris K, Deurinck M, Cormack F, Anderson JJ, Bott NT, Peremen Z, Issachar G, Laufer O, Joachim D, Jagesar RR, Jongs N, Kas MJ, Zhuparris A, Zuiker R, Recourt K, Zuilhof Z, Cha JH, Jacobs GE

Frontiers in psychiatry, 2021 Jun

View publication
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation

Patricio O’Donnell, Francis M. Dijkstra, Ugur Damar, Lei Quanhong, Annika A. de Goede, Lin Xu, Andres Pascual-Leone, Derek L. Buhl, Rob Zuiker, Titia Q. Ruijs, Jules A. A. C. Heuberger, Paul MacMullin, Martin Lubell, Mahnaz Asgharnejad, Venkatesha Murthy, Alexander Rotenberg, Gabriel E. Jacobs & Laura Rosen

Translational Psychiatry, 2021 May

View publication

«
1
2
3
4
5
6
7
8
...
13
14
»